ScholarIQanswers from OpenAlex & ORCID
Lloyd Paul Aiello
ResearcherPublications, citations & collaboration network
Lloyd Paul Aiello is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lloyd Paul Aiello have?
ScholarIQindexed works
Lloyd Paul Aiello has 472 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lloyd Paul Aiello have?
ScholarIQcitation count
Lloyd Paul Aiello has 35,068 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lloyd Paul Aiello?
ScholarIQh-index
Lloyd Paul Aiello has an h-index of 89 in OpenAlex.
What is the i10-index of Lloyd Paul Aiello?
ScholarIQi10-index
Lloyd Paul Aiello has an i10-index of 212 in OpenAlex.
What is the ORCID of Lloyd Paul Aiello?
ScholarIQorcid
The ORCID for Lloyd Paul Aiello is on the source record.
What is the OpenAlex record for Lloyd Paul Aiello?
ScholarIQopenalex
The OpenAlex for Lloyd Paul Aiello is on the source record.
What are the most-cited papers on Lloyd Paul Aiello?
ScholarIQmost cited works
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
Lloyd Paul Aiello, Robert L. Avery, Paul G. Arrigg, Bruce A. Keyt, Henry Jampel, Sabera T. Shah, Louis R. Pasquale, Hagen Thieme, Mami Iwamoto, John E. Park, Van Hung Nguyen, Lloyd M. Aiello, Napoleone Ferrara, George L. King
A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema
Emmett T. Cunningham, Anthony P. Adamis, Michael M. Altaweel, Lloyd Paul Aiello, Neil M. Bressler, Donald J. D’Amico, Mauro Goldbaum, David R. Guyer, Barrett Katz, Manju Patel, Steven D. Schwartz
Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study
Hillary A. Keenan, Jennifer K. Sun, Jared Levine, Alessandro Doria, Lloyd Paul Aiello, George S. Eisenbarth, Susan Bonner‐Weir, George L. King
Preventive Eye Care in People With Diabetes Is Cost-Saving to the Federal Government: Implications for health-care reform
Jonathan C. Javitt, Lloyd Paul Aiello, Yen-Pin Chiang, Frederick L. Ferris, Joseph K. Canner, Sheldon Greenfield
Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration
Jennifer K. Sun, Hillary A. Keenan, Jerry D. Cavallerano, Bela F. Asztalos, Ernst J. Schaefer, David R. Sell, Christopher Strauch, Vincent M. Monnier, Alessandro Doria, Lloyd Paul Aiello, George L. King